Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) was up 2.8% during mid-day trading on Friday . The company traded as high as $3.40 and last traded at $3.35, with a volume of 101,829 shares trading hands. The stock had previously closed at $3.26.

A number of equities research analysts have issued reports on DRNA shares. Stifel Nicolaus decreased their price objective on Dicerna Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, May 10th. Jefferies Group reiterated a “buy” rating and issued a $19.00 price target on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Leerink Swann reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Finally, Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a report on Thursday, May 12th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Dicerna Pharmaceuticals currently has an average rating of “Buy” and an average price target of $11.85.

The firm’s market cap is $69.32 million. The firm has a 50 day moving average of $3.36 and a 200 day moving average of $4.20.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.09. Analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.17) EPS for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.